Isotype-Specific Autoantibody Signatures in Cancer and Sepsis Samples through Multiplex Profiling  

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B587
Abstract ID: 7911

Presenting Author:
Brooke Gilliam , Product Manager at MilliporeSigma

Abstract:

Many diseases can be characterized by specific autoantibodies. The Luminex® multi-analyte profiling platform enables simultaneous detection a panel of autoantibodies in a single assay with minimal sample volume. MILLIPLEX® multiplex assays include the 15-plex Human Cancer Autoantibody Panel, 23-plex Human Cytokine Autoantibody Panel, and 20-plex Human Autoimmune Autoantibody Panel, allowing qualitative profiling of autoantibodies in serum and plasma samples. In this study, we focused on detecting cancer-associated autoantibodies and anti-cytokine autoantibodies in breast cancer, colorectal cancer, sepsis, and healthy control samples (n ≥ 20 in each group). We used the Luminex® 200™ system and the xMAP® INTELLIFLEX DRSE instrument for analysis. Preliminary data revealed anti-cytokine IgG autoantibodies against multiple cytokines (e.g., IL-2, IL-4, IFNγ) in cancer, sepsis, and healthy individuals. Additionally, certain cytokine autoantibodies (e.g., IL-1α, IL-12p40, IL-6) were detected in the tested disease samples but not in healthy controls. Isotype profiling demonstrated increased detection of cancer-associated autoantibodies by combining IgG and IgM signatures in cancer samples (e.g., p53, CCNB1/Cyclin B1, SOX2, CTAG1B/NY-ESO-1, Her2/ErbB2). We believe this robust MILLIPLEX® autoantibody detection and comprehensive isotype profiling can guide further research on autoantibodies as translational biomarkers in a clinical setting.